Reply  by Gebel, James M.
which (as he disclosed) gives speaker bureau support and clinical
research support to Dr. Gebel.
Consider my representative patient recently admitted to the
hospital with a transient ischemic attak (TIA) shortly after
drug-eluting stent implantation for in-stent restenosis. The neu-
rologist and internist stopped his aspirin and clopidogrel and put
him on Aggrenox. The patient thought this sounded wrong, and
he asked them to check with me but they did not. Fortunately, I
walked into the patient’s room to do a consult on his roommate,
discovered the error, corrected it, and the patient did well.
However, if my patient had been in a private room, if I had not
been on consult, if no cardiology consult had been ordered on his
roommate, or if my patient had been out of the room when I
arrived, he could have developed subacute stent thrombosis with its
associated 50% mortality rate. But for an extremely lucky series of
coincidences my patient could have died.
When I asked the other physicians why they did this, one stated
that the Management of Atherothrombosis in High-risk Patients
with Recent Transient Ischemic Attack or Ischemic Stroke
(MATCH) trial showed that Aggrenox was better than clopi-
dogrel for prevention of stroke and presented handouts from a
recent talk that had clearly been sponsored by the makers of
Aggrenox (directly or indirectly). The handouts bore a striking
resemblance to Dr. Gebel’s opinion piece. As we know, the
MATCH trial did not include Aggrenox, but compared acetyl-
salicylic acid (ASA) to clopidogrel or clopidogrel plus aspirin (2).
Interestingly, whether by oversight or for purposes of obfuscation, the
50-mg subtherapeutic aspirin dose in the Second European Stroke
Prevention Study (ESPS-2) is not mentioned either in Dr. Gebel’s
report (1) or in the talk handout. The clever design of the presentation
leads the listener to believe Aggrenox has done the appropriate
research to compare itself to clopidogrel or therapeutic doses of aspirin
to demonstrate efficacy and safety in cardiovascular patients; it has not.
The widely cited ESPS-2 trial compared Aggrenox to 50 mg of
aspirin daily; 50 mg of aspirin daily is not a therapeutic dose. In the
Antithrombotic Trialists’ meta-analysis, no benefit was seen of
aspirin over placebo with doses of aspirin 75 mg daily (3). In the
Women’s Health Study, no benefit was seen of aspirin 100 mg
every other day compared to placebo (4). These results suggest that
the majority of the benefit seen in the ESPS-2 trial was due to
subtherapeutic aspirin dosing, not to a dramatic benefit of Ag-
grenox. Even with this subtherapeutic dosing, aspirin had a 21%
relative risk reduction (RRR) in myocardial infarctions. One would
expect a greater RRR with therapeutic aspirin dosing.
Tran and Anand published a balanced review of this topic in
2004 (5). Their recommendation, based on viable therapeutic
alternatives, prior adverse experiences with dipyridamole, and only
a single clinical trial showing benefit of Aggrenox (in which it was
compared to subtherapeutic doses of aspirin), is that Aggrenox
should be avoided until data are available from ongoing clinical trials.
At last year’s cardiology meetings, there were multiple reports in
verbal presentations of drug-eluting stent thrombosis in patients
being treated with aspirin and dipyridamole. The implication was
that these were non-U.S. patients. Under these circumstances,
these data would not be reported to the Food and Drug Admin-
istration (FDA). Given the aggressive marketing campaign being
run by Boehringer Ingelheim, cardiologists must be very vigilant in
protecting their patients. Perhaps the FDA could withdraw Ag-
grenox from the market until it has shown superiority, equivalence,
or noninferiority to therapeutic doses of aspirin (75 mg daily, or
preferably 81 mg as is used in U.S. practice). Perhaps the FDA
could do a black box warning and letter against its use in coronary
stent patients. Perhaps individual institutions can remove it from
their formularies or place it on restricted formularies so that a
cardiologist, not a neurologist or primary care physician, must
review each case to limit the potential for harm in withdrawal of
effective antiplatelet therapy in high-risk patients.
Finally, this issue is likely to be more critical now that Aggrenox
representatives will be carrying around copies of this opinion piece,
and the neurologists and primary care providers will say that they
read a study in JACC stating that “clinical trial data support the use
of ER-DP plus aspirin [Aggrenox], but not clopidogrel plus
aspirin, to prevent secondary vascular events after stroke of TIA”
(1). Unfortunately, this is because the appropriately designed trials
have not been done, not because Aggrenox has documented
superiority, equivalence, or even noninferiority to any other ther-
apeutic antiplatelet regimen.
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REPLY
Stick to the obvious.
—Dennis Whitehead (my 11th-grade biology teacher)
It was with surprise and disappointment that I read the “letter” to
the editor authored by Dr. Horton.
If I am interpreting Dr. Horton’s missive correctly, the follow-
ing summarize her major points of concern or contention, which I
will respond to respectively:
1. It is inappropriate to withdraw aspirin plus clopidogrel therapy in
patients in the periprocedural period following coronary artery
stent placement, even if they suffer a periprocedural stroke/transient
ischemic attack (TIA). My report (1) was not intended to
comment on the appropriate use of antiplatelet medications in
patients undergoing recent coronary artery angioplasty and
stenting, or patients with acute coronary syndromes, for whom
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data overwhelmingly support at least the short-term use of
aspirin plus clopidogrel. Furthermore, I am not an expert in
this area and feel it would be inappropriate for me as a
neurologist to publish an editorial review in a cardiology
journal on such a topic. Most cardiologists are quite familiar
with these data, whereas many cardiologists (in my community
at least) are not aware of the results of Management of
Atherothrombosis in High-Risk Patients with Recent Isch-
emic Attack or Ischemic Stroke (MATCH) trial, which were
presented and published outside America, nor of the Second
European Stroke Prevention Study (ESPS-2) trial, a stroke-
focused clinical trial also conducted abroad. It is evident, in
fact, that Dr. Horton herself has either not read or has
misunderstood the MATCH trial, because she states incor-
rectly in her letter that the MATCH trial “compared acetyl-
salicylic acid (ASA) to clopidogrel or clopidogrel plus aspirin.”
The trial, in fact, compared aspirin plus clopidogrel to clopi-
dogrel alone. I cannot respond to Dr. Horton’s unreferenced
overseas case report presentations regarding any association
between aspirin plus extended-release dipyridamole causing
in-stent thrombosis, other than to reiterate that it is important
to differentiate clinical trials of acute cardiovascular and cere-
brovascular event therapy from long-term secondary preven-
tion trials. I did at one point discuss the possibility of a
multiple patient scenario review with the JACC editorial board;
however, word limitations would require a scant and inade-
quate review of multiple scenarios as opposed to a more
thorough review focused on what I regard as a common and
highly relevant single scenario.
My review was an effort to communicate formally as a stroke
neurologist and clinical trialist to my cardiology colleagues an
evidence-based perspective on a very important topic, hoping it
would stimulate the kind of productive discourse between
colleagues, which is apparently lacking at times in Dr. Hor-
ton’s own clinical practice. I would think that a similar editorial
and review of antithrombotic therapy use in acute coronary
syndrome and/or post-stenting data published in a leading
neurological journal by an intellectually honest cardiologist
interested in continuing such discourse would be a much more
appropriate and productive response to my editorial rather
than a rant to the editor of JACC impugning my scientific
integrity and ironically filled with the sorts of half-truths and
inaccuracies that its author is insinuating were present in my
review.
2. I am a hack for Boehringer-Ingelheim, and my editorial was based
on an “Aggrenox” (aspirin plus extended-release dipyridamole)
handout of some sort and is a covert “advertisement” for this
product. Let me begin by pointing out that I did not see any
conflict-of-interest disclosures in Dr. Horton’s letter. The sole
research support that I (and thousands of other investigators)
receive from Boehringer-Ingelheim is for enrollment of pa-
tients into the Prevention Regimen for Effectively Avoiding
Second Strokes (PROFESS) trial, a study that is seeking to
answer exactly the criticism that Dr. Horton complains about
in her letter, namely a lack of direct comparison between
clopidogrel and aspirin plus extended-release dipyridamole.
We will know soon enough whether any of these preparations
is “subtherapeutic.” No handouts from any pharmaceutical
company were utilized in the preparation of my manuscript,
and the opinions regarding data interpretation are entirely
my own.
3. A 50-mg dose of aspirin is ineffective and is an invalid comparison
dose against another antiplatelet drug/drug combination. This is a
point that has been and will be debated for decades, and it
depends on what end points and study population one focuses
upon. Numerous trials support the efficacy of 50-mg and even
lower doses of aspirin for stroke/TIA prevention, including the
Dutch and British TIA studies. It is my opinion that 50
mg/day of aspirin is, if anything, a more than adequate dose to
prevent subsequent vascular events in most TIA/stroke pa-
tients, because the majority of recurrent vascular events in such
patients are recurrent ischemic strokes, at least during the 1.5-
to five-year time frame investigated by modern-era antiplatelet
drug clinical trials.
Additionally, the American Stroke Association, National
Stroke Association, American Heart Association, American
College of Chest Physicians, and the Food and Drug Admin-
istration (FDA) all disagree with Dr. Horton’s interpretation
of these data and include 50 mg/day in their recommended
acceptable dose range of aspirin for stroke/TIA prevention.
Ever since I submitted my manuscript, the important Women’s
Health Study (2) has indeed been published, and contrary to
Dr. Horton’s assertions of no benefit, it showed a statistically
significant 24% relative risk reduction in ischemic stroke (p 
0.03) in this primary prevention cohort of women using 100
mg of aspirin every other day, which is otherwise irrelevant to
the focus of my manuscript, namely secondary vascular event
prevention in TIA and stroke patients. It does, once again,
demonstrate Dr. Horton’s unfamiliarity with the data she is
citing to support her arguments; and contrary to her assertions,
this in fact adds another piece of strong evidence supporting
the efficacy of 50 mg of aspirin per day in preventing ischemic
stroke (albeit not myocardial infarction [MI] or vascular
death). For those physicians uncomfortable with a 50-mg dose
of aspirin in patients with known coronary artery disease and
the lack of sufficient data to establish efficacy in MI prevention
for aspirin doses below 75 mg/day, the obvious simple solution
is to prescribe additional aspirin for such a patient.
4. The FDA should require a warning for “Aggrenox” regarding it
not being used postacute coronary syndrome/stent. Again, it is
obvious that Dr. Horton has not read the Aggrenox package
insert, which already does and always has included such a
warning. The “precautions” section of the package insert
specifically states the following: “Coronary Artery Disease:
Dipyridamole has a vasodilatory effect and should be used with
caution in patients with severe coronary artery disease (e.g.,
unstable angina or recently sustained myocardial infarc-
tion). . . . For stroke or TIA patients for whom aspirin is
indicated to prevent recurrent MI or angina pectoris, the aspirin
in this product may not provide adequate treatment for the
cardiac indications.” To the best of my knowledge, this product is
neither FDA-approved nor marketed for any cardiac indication.
5. Boehringer-Ingelheim is engaged in an aggressive marketing
campaign for “Aggrenox.” I cannot speak for Boehringer-
Ingelheim or its marketing practices or comment on any
“handout” that I have not seen, but I will mention what I have
seen first-hand, namely that the manufacturers of clopidogrel
continued to air direct-to-consumer television commercials
advising patients to ask their doctor about adding Plavix to
aspirin to prevent another heart attack or stroke, even subse-
quent to the publication of the MATCH trial.
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I look forward to the results of the many ongoing clinical
trials that will further define the role of antiplatelet medica-
tions in vascular-event prevention, acute stroke, and carotid
stenting. In the interim, I will continue to respect the opinions
of colleagues whose interpretation of currently available data
differs from my own even when they do not respect mine.
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